Prothena And Novo Nordisk Announce Definitive Purchase Agreement Under Which Novo Nordisk Acquired Prothena's PRX004 And Broader ATTR Amyloidosis Program; Prothena Eligible To Receive $1.2B In Sales Milestones Including $100M In Upfront/Near-Term Payments